Skip to main content
Top

04-06-2018 | Biologics | Article

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis

Journal: Clinical Rheumatology

Authors: Arthur Kavanaugh, Rakesh Singh, Chitra Karki, Carol J. Etzel, Joel M. Kremer, Jeffrey D. Greenberg, Jenny Griffith

Publisher: Springer London

Abstract

To compare disease burden and biologic use among psoriatic arthritis (PsA) or rheumatoid arthritis (RA) patients recruited to the Corrona registry. Retrospective study of patients with PsA or RA enrolled in Corrona between January 2002 and March 2013 and grouped in 2-year intervals. Clinical outcomes and biologic use were assessed. Biologic use increased over time in both cohorts, with 62 and 52% of patients with PsA and RA, respectively, receiving biologics by 2012–2013. However, 25 and 35% of patients with PsA and RA, respectively, continued to experience moderate/high disease activity. Overall, the progressive increase in biologic use accompanied progressive decreases in Clinical Disease Activity Index (from 14.2 to 10.4 for RA, and 12.4 to 8.1 for PsA) and mean Health Assessment Questionnaire score (from 0.36 to 0.34, and 0.3 to 0.24). Mean patient pain, the proportion of patients reporting morning stiffness, and the mean duration of morning stiffness remained similar for both cohorts. PsA and RA treated in the rheumatology setting had a comparable impact on patient quality of life and functional ability. Disease burden improved with increased biologic utilization in both groups; however, moderate/severe disease remains in a significant proportion of PsA and RA patients.
Literature
1.
Reich K, Kruger K, Mossner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047. https://​doi.​org/​10.​1111/​j.​1365-2133.​2008.​09023.​x CrossRefPubMed
2.
Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am 41:545–568. https://​doi.​org/​10.​1016/​j.​rdc.​2015.​07.​001 CrossRef
3.
Yamamoto T (2011) Psoriatic arthritis: from a dermatological perspective. Eur J Dermatol 21:660–666. https://​doi.​org/​10.​1684/​ejd.​2011.​1452 PubMedCrossRef
4.
Coates LC, Helliwell PS (2017) Psoriatic arthritis: state of the art review. Clin Med (Lond) 17:65–70. https://​doi.​org/​10.​7861/​clinmedicine.​17-1-65 CrossRef
5.
Uhlig T, Moe RH, Kvien TK (2014) The burden of disease in rheumatoid arthritis. PharmacoEconomics 32:841–851. https://​doi.​org/​10.​1007/​s40273-014-0174-6 CrossRefPubMed
6.
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316–1322. https://​doi.​org/​10.​1136/​annrheumdis-2013-204627 CrossRefPubMed
7.
Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 35:680–689PubMedPubMedCentral
8.
Borman P, Toy GG, Babaoglu S, Bodur H, Ciliz D, Alli N (2007) A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 26:330–334. https://​doi.​org/​10.​1007/​s10067-006-0298-y CrossRefPubMed
9.
Mease PJ (2009) Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum 38:320–335. https://​doi.​org/​10.​1016/​j.​semarthrit.​2008.​01.​003 CrossRefPubMed
10.
Tillett W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, McHugh N (2013) Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 72:1358–1361. https://​doi.​org/​10.​1136/​annrheumdis-2012-202608 CrossRefPubMed
11.
Gladman DD, Thavaneswaran A, Chandran V, Cook RJ (2011) Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 70:2152–2154. https://​doi.​org/​10.​1136/​ard.​2011.​150938 CrossRefPubMed
12.
Haroon M, Gallagher P, FitzGerald O (2015) Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 74:1045–1050. https://​doi.​org/​10.​1136/​annrheumdis-2013-204858 CrossRefPubMed
13.
Boyd T, Kavanaugh A (2016) Novel approaches to biological therapy for psoriatic arthritis. Expert Opin Biol Ther 16:173–186. https://​doi.​org/​10.​1517/​14712598.​2016.​1118045 CrossRefPubMed
14.
Mease P (2006) Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 8:348–354CrossRefPubMed
15.
Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, Kremer J, Setoguchi S, Solomon DH, Xie F, Yun H (2014) Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken) 66:1790–1798. https://​doi.​org/​10.​1002/​acr.​22377 CrossRef